Form 4: REGENXBIO Director Receives Equity Compensation

Director David C. Stump was granted 9,807 restricted stock units and 46,600 stock options by REGENXBIO Inc.

Summary

• Director David C. Stump received an equity grant consisting of 9,807 restricted stock units (RSUs) and 46,600 stock options.
• The RSUs and stock options are scheduled to vest in full on May 29, 2027, contingent upon continued service to the company.
• The stock options have an exercise price of $7.01 per share and an expiration date of May 29, 2036.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 28,861 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the company's operational outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention mechanism established via time-based vesting requirements.

Negatives

• Dilutive impact on existing shareholders due to the issuance of new equity and options.

Risks

• Potential for future dilution if options are exercised.
• Dependence on continued service for the vesting of equity awards.

Future Outlook

The equity grants are subject to continuous service requirements, indicating a focus on long-term director retention through May 2027.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is standard practice in the biotechnology sector to align leadership incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices in the U.S. biotech industry.
• Grant sizes are typical for non-employee director compensation packages in mid-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity awards on May 29, 2027.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Insider Trading, Equity Compensation, Director Compensation